Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

VLA-4 receptor-blocking drugs described by Zeneca

Aug. 30, 1996

Cyclooxygenase-2-inhibitors described by Japan Tobacco

Aug. 23, 1996

Alexion's C5 complement inhibitor effective in murine lupus model

Aug. 23, 1996

Cyclooxygenase-2 inhibitors from Merck Frosst

Aug. 23, 1996

Hyanalgese-D demonstrates negative efficacy in U.S. phase III trial

Aug. 23, 1996

KF-20444: Kyowa Hakko's novel antirheumatic agent

Aug. 23, 1996

Antiarthritic MMP inhibitor described by Chugai

Aug. 16, 1996

Kureha discloses MMP-inhibitory esculetin derivatives

Aug. 16, 1996

Nisshin Flour Milling describes agents for septic shock

Aug. 16, 1996

P-selectin inhibitors reported by BMS

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.